54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
13 citations
,
November 2012 in “PubMed” 5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
January 2018 in “Surgical and Cosmetic Dermatology” 5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
4 citations
,
July 2020 in “Research Square (Research Square)” The research helps understand how finasteride works and aids drug development.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
14 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” December 2013 in “The Journal of Urology”
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
27 citations
,
October 2001 in “Journal of Medicinal Chemistry” Researchers found new potential but less potent rat enzyme inhibitors using a 3D model.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
31 citations
,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
January 2011 in “Medical Recapitulate” 5α-reductase enzyme affects hormone levels, influencing conditions like acne and hair loss.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.